Immunocore (IMCR) Competitors $33.56 +0.03 (+0.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$33.54 -0.02 (-0.04%) As of 10/17/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. GRFS, NUVL, AXSM, LEGN, PCVX, MTSR, PTGX, TGTX, PTCT, and KRYSShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), Vaxcyte (PCVX), Metsera (MTSR), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Grifols Nuvalent Axsome Therapeutics Legend Biotech Vaxcyte Metsera Protagonist Therapeutics TG Therapeutics PTC Therapeutics Krystal Biotech Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Do analysts rate GRFS or IMCR? Grifols currently has a consensus target price of $10.30, indicating a potential upside of 6.74%. Immunocore has a consensus target price of $56.89, indicating a potential upside of 69.51%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50Immunocore 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to GRFS or IMCR? In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 1 mentions for Grifols and 0 mentions for Immunocore. Grifols' average media sentiment score of 0.79 beat Immunocore's score of 0.00 indicating that Grifols is being referred to more favorably in the media. Company Overall Sentiment Grifols Positive Immunocore Neutral Which has more risk & volatility, GRFS or IMCR? Grifols has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Is GRFS or IMCR more profitable? Grifols has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Immunocore -5.70%-5.40%-1.93% Do institutionals & insiders have more ownership in GRFS or IMCR? 84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, GRFS or IMCR? Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.85$169.80M$1.178.25Immunocore$310.20M5.45-$51.09M-$0.40-83.90 SummaryGrifols beats Immunocore on 11 of the 17 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69B$3.44B$6.19B$10.56BDividend YieldN/A2.27%5.70%4.81%P/E Ratio-83.9023.0185.5427.13Price / Sales5.45481.75608.39130.24Price / CashN/A46.9237.1060.81Price / Book4.6610.4112.236.52Net Income-$51.09M-$52.77M$3.33B$276.93M7 Day Performance3.58%2.31%1.17%1.93%1 Month Performance2.94%12.59%6.85%2.19%1 Year Performance-2.39%11.18%58.93%34.62% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.9638 of 5 stars$33.56+0.1%$56.89+69.5%-2.4%$1.69B$310.20M-83.90320GRFSGrifols3.7457 of 5 stars$9.45+1.4%$10.30+9.0%+11.6%$6.41B$7.81B8.0823,822NUVLNuvalent2.8341 of 5 stars$89.75+1.9%$118.89+32.5%-10.8%$6.35BN/A-18.3240Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionAXSMAxsome Therapeutics4.7305 of 5 stars$121.15-0.5%$177.93+46.9%+37.1%$6.07B$385.69M-23.90380Positive NewsAnalyst RevisionLEGNLegend Biotech3.0839 of 5 stars$32.85+3.6%$69.25+110.8%-25.4%$5.85B$627.24M-37.332,609News CoverageAnalyst ForecastHigh Trading VolumePCVXVaxcyte2.3312 of 5 stars$43.81+0.3%$106.25+142.5%-63.3%$5.67BN/A-10.66160News CoverageAnalyst ForecastMTSRMetseraN/A$52.97+0.2%$55.75+5.2%N/A$5.55BN/A0.0081PTGXProtagonist Therapeutics1.9306 of 5 stars$79.17-9.0%$72.00-9.1%+65.0%$5.41B$434.43M113.10120Analyst ForecastInsider TradeHigh Trading VolumeTGTXTG Therapeutics4.5119 of 5 stars$34.22+1.4%$49.00+43.2%+48.7%$5.36B$329M92.49290Positive NewsPTCTPTC Therapeutics3.3414 of 5 stars$66.06-0.3%$69.00+4.5%+68.7%$5.26B$806.78M9.481,410Analyst RevisionKRYSKrystal Biotech4.7806 of 5 stars$184.74+1.8%$209.00+13.1%+6.2%$5.25B$290.52M37.55210News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies GRFS Competitors NUVL Competitors AXSM Competitors LEGN Competitors PCVX Competitors MTSR Competitors PTGX Competitors TGTX Competitors PTCT Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
